Eli Lilly and Company (LLY)
Eli Lilly stumbles as weight-loss drug sales less than expected
Shares in Eli Lilly and Co fell 6.4% after the drugmaker said sales of its Mounjaro and Zepbound weight-loss medications grew more slowly than it had expected. CEO David Ricks said the US market for incretins – the drugs that target hormones in the gut – grew at 45% compared to the same quarter last year but the company's previous guidance had anticipated an "even faster acceleration".Click Here Combined with lower-than-expected inventory of these tirzepatide-based drugs at year-end, this led to fourth-quarter revenue coming in lower than forecast.
Eli Lilly lowers FY revenue forecast as weight loss drug sales fall short
Shares in Eli Lilly and Co (NYSE:LLY) fell 7.3% after the drugmaker said sales of its Mounjaro and Zepbound weight-loss medications grew more slowly than it had expected. CEO David Ricks said the US market for incretins – the drugs that target hormones in the gut – grew at 45% compared to the same quarter last year but the company's previous guidance had anticipated an "even faster acceleration".
Eli Lilly CEO on prospect of insurance companies covering weight loss drugs
Eli Lilly CEO David Ricks discusses the potential of insurance companies covering weight loss drugs saying they will “recognize it's the ultimate prevention medication.”
Eli Lily cuts 2024 revenue guidance by $400M, shares sink 8%
Eli Lilly saw its shares crash in early trade on Tuesday as the pharm major provided its revenue outlook for 2024 and 2025. The pharma major cut its revenue guidance for the year leading to an around 8% dip in its shares.
Lilly's Zepbound and Mounjaro Sales Miss Estimates Again. The Wobble's Looking Serious.
It was the second consecutive miss for the two closely watched obesity and Type 2 diabetes drugs.
Eli Lilly Cuts Sales Outlook After Sluggish Growth for Incretin Drugs
Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.
Eli Lilly CEO David Ricks: Projecting 32% total growth for company in 2025
Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the weight loss drugs market, status of the weight loss drug pill, revised guidance, and more.
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Shares dropped about 6%.
Mounjaro and Zepbound sales disappoint, and Eli Lilly's stock is dropping
Eli Lilly's stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and Zepbound missed expectations.
Lilly forecasts weak sales of weight-loss drug in fourth quarter
Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street expectations in the fourth quarter, but forecast 2025 revenue largely above estimates.
Healthcare sector poised for rebound in 2025
The JPMorgan Healthcare Conference is a place where deals happen. As the conference kicked off, deals were announced from Eli Lilly (LLY), Johnson & Johnson (JNJ), and GSK (GSK).
